Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment

• Status: Recruiting
• Trial end date: 2026-06-23
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of trametinib in juvenile patients with histiocytosis resistant to conventional therapy and without the BRAF gene mutation or after the failure of vemurafenib treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anna Raciborska
• Collaborators: Łukasiewicz Research Network; Maria Sklodowska-Curie Institute - Oncology Center; Wrocław University of Environmental and Life Sciences
• Treatments: Trametinib

Criteria

Inclusion Criteria:

1. Lack of mutations in the BRAF gene in tumor tissues and/or ctDNA at any stage of treatment or follow-up, or failure of Vemurafenib treatment in BRAF positive patients.

2. Failure of the treatment (at least one of below needs to apply in order for this requirement to be satisfied):

1. Progression on the I and II line treatment, and involving of a minimum one risk organ; previous treatment should include a minimum of 6 weeks of weekly Vinblastine with a minimum of 28 days prednisolone or minimum 2 cycles of Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a treatment of 2 line, or

2. Disease reactivation after an initial response to treatment with Vimblastine and prednisolone as the first line and no response to treatment of the second line using a minimum of 2 cycles of one of two drugs: Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a treatment of 2 line and the involving of a minimum one risk organ, or

3. Third or subsequent reactivation of disease with or without risk organ involvement, or

4. Progression during Vemurafenib therapy, or

5. Reactivation of disease after Vemurafenib therapy has been completed, or

6. The appearance of signs of neurodegenerative disorder (ND) in MRI of the CNS.

3. Signing of informed consent for trial participation (including for Trametinib treatment) according with current legal regulations.

4. Consent to the use of effective contraception throughout the Trametinib administration period and a minimum of 1 year after discontinuation in patients at puberty and sexual maturity.

5. Participation in HISTIOGEN trial.

Exclusion Criteria:

1. Lack of inclusion criteria.

2. Pregnancy and breastfeeding .

3. Hypersensitivity to the study drug or any of its ingredients.

4. Iritis, uveitis, obstruction of the retinal veins.

5. Simultaneous treatment with other drugs which might interact with Trametinib.

6. Persistent toxicity related to prior therapy, making it impossible to treat with Trametinib.

7. Diagnosis of other malignancies before study inclusion.

8. Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.